换一批
换一批Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer.
第一作者：
Adam R,Wolfe
第一单位：
Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Arthur G. James Comprehensive Cancer Center and Richard J. Solove Research Institute, Columbus, Ohio.
作者：
主题词
白蛋白类(Albumins);动物(Animals);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);癌, 胰腺管(Carcinoma, Pancreatic Ductal);窖蛋白1(Caveolin 1);细胞周期(Cell Cycle);细胞系, 肿瘤(Cell Line, Tumor);细胞增殖(Cell Proliferation);脱氧胞苷(Deoxycytidine);用药计划表(Drug Administration Schedule);基因表达调控, 肿瘤(Gene Expression Regulation, Neoplastic);人类(Humans);男(雄)性(Male);小鼠, 近交NOD(Mice, Inbred NOD);小鼠, 基因敲除(Mice, Knockout);小鼠, 裸(Mice, Nude);小鼠, SCID(Mice, SCID);紫杉酚(Paclitaxel);胰腺肿瘤(Pancreatic Neoplasms);治疗结果(Treatment Outcome);肿瘤负荷(Tumor Burden);异种移植模型抗肿瘤试验(Xenograft Model Antitumor Assays);小鼠(Mice)
DOI
10.1158/1078-0432.CCR-20-1422
PMID
33087331
发布时间
2024-02-26
- 浏览0
Clinical cancer research
554-565页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
